Winslow Capital Management
ALXN

Winslow Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Winslow Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-17
Closed -$2K – 100
2018
Q2 		$2K Hold
17
– – ﹤0.01% 83
2018
Q1 		$2K Hold
17
– – ﹤0.01% 83
2017
Q4 		$2K Hold
17
– – ﹤0.01% 91
2017
Q3 		$2K Hold
17
– – ﹤0.01% 86
2017
Q2 		$2K Sell
17
-40
-70% -$4.66K ﹤0.01% 86
2017
Q1 		$7K Sell
57
-2,131,396
-100% -$275M ﹤0.01% 75
2016
Q4 		$261M Buy
2,131,453
+2,131,134
+668,067% +$261M 1.2% 34
2016
Q3 		$39K Sell
319
-26
-8% -$3.35K ﹤0.01% 142
2016
Q2 		$40K Sell
345
-3,134,207
-100% -$445M ﹤0.01% 136
2016
Q1 		$436M Buy
3,134,552
+70,421
+2% +$10.3M 1.71% 20
2015
Q4 		$584M Sell
3,064,131
-147,025
-5% -$25.7M 2.09% 15
2015
Q3 		$502M Buy
3,211,156
+321,355
+11% +$58.6M 1.83% 18
2015
Q2 		$522M Buy
2,889,801
+916,750
+46% +$158M 1.74% 19
2015
Q1 		$342M Sell
1,973,051
-1,375,951
-41% -$249M 1.05% 47
2014
Q4 		$620M Sell
3,349,002
-18,084
-0.5% -$3.35M 1.91% 15
2014
Q3 		$558M Buy
3,367,086
+493,654
+17% +$81.1M 1.71% 20
2014
Q2 		$449M Buy
2,873,432
+44,057
+2% +$6.96M 1.37% 26
2014
Q1 		$430M Sell
2,829,375
-568,578
-17% -$90.4M 1.35% 28
2013
Q4 		$452M Buy
3,397,953
+631,826
+23% +$75.8M 1.33% 30
2013
Q3 		$321M Sell
2,766,127
-1,419,963
-34% -$156M 1.04% 47
2013
Q2 		$386M Buy
+4,186,090
New +$403M 1.26% 36

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Winslow Capital Management's ALXN Position: Q3 2018 in Review

Winslow Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2018, closing a stake of 17 shares — an estimated $2K sold.

Winslow Capital Management first reported a position in ALXN in Q2 2013 and held it in 21 quarters. The position peaked at $620M in Q4 2014. 585 funds tracked by Wall St. Rank hold ALXN as of Q3 2018.

  • Winslow Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Winslow Capital Management sold 17 Alexion Pharmaceuticals shares in Q3 2018, an estimated $2K.
  • Winslow Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 21 quarters.
  • Winslow Capital Management's Alexion Pharmaceuticals position peaked at $620M in Q4 2014.
  • 585 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2018.

Based on Winslow Capital Management's 13F filing for Q3 2018, filed 9 Nov 2018.